As of 2025-07-10, the Intrinsic Value of Nanjing Vishee Medical Technology Co Ltd (688580.SS) is 23.36 CNY. This 688580.SS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 45.03 CNY, the upside of Nanjing Vishee Medical Technology Co Ltd is -48.10%.
The range of the Intrinsic Value is 20.56 - 28.85 CNY
Based on its market price of 45.03 CNY and our intrinsic valuation, Nanjing Vishee Medical Technology Co Ltd (688580.SS) is overvalued by 48.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 20.56 - 28.85 | 23.36 | -48.1% |
| DCF (Growth 10y) | 24.72 - 36.44 | 28.70 | -36.3% |
| DCF (EBITDA 5y) | 63.88 - 110.82 | 88.75 | 97.1% |
| DCF (EBITDA 10y) | 61.51 - 116.70 | 88.55 | 96.6% |
| Fair Value | 9.64 - 9.64 | 9.64 | -78.59% |
| P/E | 36.19 - 67.47 | 45.98 | 2.1% |
| EV/EBITDA | 34.65 - 59.31 | 45.83 | 1.8% |
| EPV | 10.44 - 10.34 | 10.39 | -76.9% |
| DDM - Stable | 7.74 - 19.62 | 13.68 | -69.6% |
| DDM - Multi | 13.03 - 26.50 | 17.56 | -61.0% |
| Market Cap (mil) | 4,312.52 |
| Beta | 1.84 |
| Outstanding shares (mil) | 95.77 |
| Enterprise Value (mil) | 3,283.83 |
| Market risk premium | 6.13% |
| Cost of Equity | 11.08% |
| Cost of Debt | 5.00% |
| WACC | 11.07% |